<DOC>
	<DOCNO>NCT01706471</DOCNO>
	<brief_summary>Calcineurin inhibitor , cyclosporine tacrolimus , improve allograft survival kidney organ transplantation . Indeed , reduce incidence acute rejection episodes cadaveric allograft recipient . Although marked progression make initial survival rate , long-term kidney graft survival yet show encouraging result . Because CNIs associate adverse effect , particularly nephrotoxicity , contribute decline organ function eventual graft loss . In kidney transplant , progressive allograft dysfunction show develop many 94 % patient 1 year . Therefore , reduce eliminate dose CNIs minimize nephrotoxicity must balance maintenance adequate immunosuppression . Certican allow CNI dose reduction provide renal function improvement current PSI strategy point early intervention important manage risk CAN develop de novo maintenance renal transplant recipient . To demonstrate Certican early introduction 1 month provide well renal function change efficacy compare standard regimen , also prevent delay wound healing .</brief_summary>
	<brief_title>Safety Efficacy Early Introduction Everolimus ( CerticanÂ® ) With Low Dose Cyclosporine de Novo Kidney Recipients After 1 Month Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Males Females age 18~65 year 2 . De novo recipient cadaveric , live unrelated living relate donor kidney transplant 3 . Received kidney transplant age 10~65years donor 4 . Willing provide write informed consent 5 . Completing study visit accord study protocol 1 . Recipients multiple organ transplant 2 . Kidney transplant nonheart beat cadaveric donor / organ donor cardiac death 3 . Recipients ABO incompatible transplant lymphocyte crossmatch positive transplant 4 . Recipients extrarenal solid organ transplant stem cell transplant 5 . Recipient/ donor know antiHCV , HIV HBsAg positive 6 . Diagnosed Cancer within past 5 year ( except complete recover squamous cell basal cell skin cancer ) 7 . Drug Hypersensitivity investigational drug relate drug Females pregnant lactate 8 . Any following laboratory abnormality screen : ALT , AST , ALP , total bilirubin &gt; 3 time upper limit ANC &lt; 1,500mm3 WBC &lt; 2,500mm3 platelet &lt; 100,000 mm3 Cholesterol &gt; 350 mg/dl 9.0 mmol/L , TG &gt; 500 mg/dl 5.6mmol/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>verLowCNI</keyword>
</DOC>